Fetoscopic Repair of Isolated Fetal Spina Bifida
NCT03090633
Arnold-Chiari Malformation, Chiari Malformation Type 2
Baltimore, Maryland, United States
View Trial DetailsNCT Number: NCT05883761
The goal of this observational study is to assess the birth outcomes of HIV-positive women delivering in hospitals in Eswatini who are receiving dolutegravir (DTG) or other anti-retroviral (ARV) drug regimens. The main question the study aims to answer is, what is the proportion of neural tube defects among live and stillborn infants delivered by:
* HIV-positive women on DTG at conception * HIV-negative women * HIV-positive women on non-DTG ARV at conception
Participants will be interviewed for information on HIV testing and antiretroviral therapy history, other medical history of selected conditions (e.g., diabetes, malaria, TB) and potential birth defect exposures. Photographs will be taken of the infants. Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) will be collected from patient records.
Looking for future studies?
Notify MeFemale
Observational
Good Shepherd Hospital, Lubombo, Lubombo Region, Eswatini
This is an observational study conducted at five high volume hospitals in Eswatini, in which birth defect and other data will be collected at the time of delivery (or hospital admission for miscarriages and medical abortions) for all women. The overall aim of this study is to evaluate the birth outcomes of HIV-positive women who are receiving DTG or other ARV drug regimens. The primary research objectives are to: 1) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-positive women on DTG at conception; 2) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-negative women; and 3) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-positive women on non-DTG ART at conception. Secondary objectives are to determine overall general prevalence of major external birth defects and other pregnancy outcomes and any associations with other factors (e.g., maternal age, gravida). Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) are collected from patient charts, registers, reporting forms and databases for all women. Women of live or stillborn infants with birth defects are consented for interviews capturing detailed history and exposure data and photographs of newborns' birth defects. Data collection will be for approximately 24 months. Blinded interview data and photographs are reviewed by a medical geneticist for confirmatory defect diagnosis. We will describe rates and 95% confidence intervals (CI) for birth defects among infants by maternal HIV and ART status.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Surveillance component includes all deliveries/admissions as defined in study population description. For a subset of the population recruited for additional data collection:
Inclusion criteria
Exclusion criteria
Time frame: 24 months
Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on DTG at conception
Time frame: 24 months
Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-negative women
Time frame: 24 months
Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on non-DTG ARV at conception
Time frame: 24 months
Number of live and stillborn infants with major external birth defects divided by the total number of live and stillborn infants among all women regardless of HIV or ART status
Time frame: 24 months
Number of live and stillborn infants with low birthweight and pre-term delivery divided by the total number of live infants among women (overall and by HIV/ART status); number of stillborn infants among all pregnancies, including miscarriages
Elizabeth Glaser Pediatric AIDS Foundation
Other
Assessment of Birth Outcomes in Eswatini After Transition to Dolutegravir-based Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03090633
Arnold-Chiari Malformation, Chiari Malformation Type 2
Baltimore, Maryland, United States
View Trial DetailsNCT06904612
Abnormalities, Severe Teratoid, Anemia
Orlando, Florida, United States
View Trial DetailsNCT03936322
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Rochester, Minnesota, United States
View Trial DetailsNCT06174883
Anencephaly-Spina Bifida, Avitaminosis
Orlando, Florida, United States
View Trial Details